Brochures

Pharma Crystallization Summit 2022 Technical Program

Bridging the Drug Substance and Drug Product Interface With the ability to develop both Drug Substance (DS) and Drug product (DP) under the same umbrella, our team enjoys a synergism absent in most CROs. The ability to bridge the DS/DP interface is a major competitive advantage, and we are able to shorten development timeline and